Rosenbaum Jay D. Lowers stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Rosenbaum Jay D. reduced its stake in Edwards Lifesciences Corp by 11.32% during the most recent quarter end. The investment management company now holds a total of 17,870 shares of Edwards Lifesciences Corp which is valued at $1,935,857 after selling 2,280 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Edwards Lifesciences Corp makes up approximately 0.36% of Rosenbaum Jay D.’s portfolio.

Edwards Lifesciences Corp opened for trading at $107.99 and hit $109.32 on the upside on Friday, eventually ending the session at $108.33, with a gain of 0.21% or 0.23 points. The heightened volatility saw the trading volume jump to 9,20,923 shares. Company has a market cap of $23,247 M.

Other Hedge Funds, Including , Community Bank N.a. reduced its stake in EW by selling 56 shares or 44.44% in the most recent quarter. The Hedge Fund company now holds 70 shares of EW which is valued at $7,583.Gulf International Bank (uk) Ltd boosted its stake in EW in the latest quarter, The investment management firm added 2,470 additional shares and now holds a total of 64,880 shares of Edwards Lifesciences Corp which is valued at $7,028,450. Edwards Lifesciences Corp makes up approx 0.12% of Gulf International Bank (uk) Ltd’s portfolio.Gateway Investment Advisers reduced its stake in EW by selling 7,473 shares or 31.66% in the most recent quarter. The Hedge Fund company now holds 16,128 shares of EW which is valued at $1,747,146. Edwards Lifesciences Corp makes up approx 0.01% of Gateway Investment Advisers’s portfolio.Bremer Trust National Association boosted its stake in EW in the latest quarter, The investment management firm added 239 additional shares and now holds a total of 4,983 shares of Edwards Lifesciences Corp which is valued at $530,939. Edwards Lifesciences Corp makes up approx 0.15% of Bremer Trust National Association’s portfolio.Dnb Asset Management As boosted its stake in EW in the latest quarter, The investment management firm added 4,600 additional shares and now holds a total of 22,746 shares of Edwards Lifesciences Corp which is valued at $2,423,586. Edwards Lifesciences Corp makes up approx 0.05% of Dnb Asset Management As’s portfolio.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Leerink Partners on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $93 .Company shares were Reiterated by Canaccord Genuity on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $95 .Company shares were Reiterated by RBC Capital Mkts on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 110 from a previous price target of $100 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.